ABSTRACT Since the calcium antagonists nifedipine and verapamil have been shown to diminish exercise induced asthma, the effect of oral diltiazem, a calcium channel blocker not previously investigated in this context, was studied. Ten patients with bronchial asthma were given 60 mg diltiazem or placebo four hours before the challenge in a double blind, randomised, crossover fashion. Exercise was performed on a cycle ergometer while the subjects were breathing cold air, resulting in a respiratory heat exchange which was similar at the two study sessions. FEV, and specific conductance (sGaw) were recorded before and three, 10, 15, and 30 minutes after the challenge. No significant differences were found between placebo and diltiazem days in the fall of FEV, or sGaw after exercise. Thus unlike other calcium antagonists diltiazem, in a dose of 60 mg given orally four hours before exercise, failed to protect against exercise induced asthma.
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Exercise induced asthma can be completely or partially inhibited by oral nifedipine'-3 or by inhaled verapamil. 4 We have investigated another calcium channel blocker, diltiazem, as no study on its ability to influence exercise induced asthma has previously been reported. As respiratory heat exchange is considered to be an initiating stimulus for exercise induced asthma,5 the effects of diltiazem and placebo were compared under carefully controlled experimental conditions designed to standardise the inhalation thermal challenge during exercise.
Methods
Patients We investigated 10 patients with bronchial asthma (five men and five women with a mean age of 27*9 years, range 19-41). Nine patients were judged atopic on the basis of positive skin test reactions to common allergens. All patients gave a history suggesting exercise induced asthma. All were non-smokers and did not require regular medication. Sympathomimetic agents, which were taken occasionally, were withheld for 12 hours before the study sessions. The patients were instructed about the aim of the study and gave their consent. figure 2 . It can be seen that the response to the challenge varied considerably between the patients. Apart from patient 1, pretreatment with diltiazem did not change the pattern of response. For the group as a whole there were no significant differences between the maximum bronchoconstriction or airway function at any specific time after the challenge on placebo and diltiazem days. With placebo and diltiazem pretreatment the mean (SD) maximum percentage falls of FEVy were 24*8 (20.1) and 21-7 (17-5). The mean (SD) maximum percentage decreases of sGaw were 66-2 (18.4) and 62*7 (23.9) respectively. The protection index calculated for each lung function measurement did not differ statistically from zero.
Discusion
In patients with exercise induced asthma diltiazem, 60 mg, taken orally four hours before exercising while they breathed cold air, did not alter the bronchoconstriction response when compared with placebo. This result clearly contrasts with the protective effect of nifedipine on exercise induced'-3 and hyperventilation induced910 asthma and with the ability of inhaled verapamil to blunt exercise induced airway obstruction.4 Three factors that could be responsible for this discrepancy must be considered-namely, the methodological, pharmacokinetic, and pharmacological aspects.
In our group of patients cold air breathing during exercise resulted in a respiratory heat exchange which was not different on the two days. As in some patients small differences in respiratory heat exchange after pretreatment with placebo and diltiazem could not be avoided, we re-evaluated the data by relating the results to the respiratory heat exchange actually measured during the study; but this again failed to show a difference between placebo and diltiazem.
Diltiazem was given as a single dose before the challenge in the same way as in the study in which the inhibitory effect of nifedipine on exercise induced asthma was most clearly documented.' The dose used is that recommended for a single oral application of diltiazem. The choice of an interval of four hours between ingestion of the capsule and the challenge is based on pharmacokinetic data showing a peak serum concentration of diltiazem between the second and fourth hour after ingestion." We therefore think it unlikely that pharmacokinetic factors are responsible for the different results.
The lack of effect of 60 mg diltiazem compared with 20 mg nifedipine could be explained simply by a relative underdosage of diltiazem. In our laboratory, however, we have shown that a 60 mg dose of diltiazem taken orally four hours before an inhalation challenge protected against histamine and carbachol induced bronchoconstriction in patients with hyperreactive airways. After diltiazem the cumulative breath units of histamine and carbachol causing a fall in sGaw of 35 % were approximately doubled (unpublished observations). As nifedipine attenuates histamine induced'2 '3 and allergen induced '4 bronchoconstriction in man and diminishes airway obstruction after antigen and methacholine inhalation in the dog'5 the ineffectiveness of diltiazem compared with nifedipine is unlikely to be simply a question of dosage. Russi et al'6 recently showed in allergic sheep that verapamil prevented bronchoconstriction induced by allergen but did not modify the airway response to histamine and carbachol challenge. These results show that the effects of different calcium channel blockers in protecting against bronchoconstriction vary with the stimuli, but further studies are required to elicit the mechanisms of their actions.
